Eficacia y seguridad de Bimekizumab en pacientes con Artritis Psoriásica Activa: Resultados de Tres Años de un Estudio de Fase IIb Aleatorizado Controlado y su Estudio de Extensión Abierto
Arthritis Rheumatol. 2022 doi: 10.1002/art.42280
This study highlighted that the safety of bimekizumab in patients with PsA over 3 years of treatment was consistent with the previous 48-week results, as well as other recently published studies of IL-17 inhibitors in PsA patients.